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Abstract A novel angiotensin-I-converting enzyme (ACE)
inhibitory peptide, designated acein-1, was isolated from the
tryptic hydrolysate of human plasma. Gel filtration and cation
exchange chromatography were performed to purify this peptide,
followed by reversed-phase gradient and isocratic high-per-
formance liquid chromatography. Acein-1 was found to be a
heptapeptide, Tyr-Leu-Tyr-Glu-Ile-Ala-Arg, corresponding to
f(138^144) of human serum albumin. The synthetic heptapeptide,
hexapeptide (Tyr-Leu-Tyr-Glu-Ile-Ala, des-7R acein-1) and
octapeptide (Tyr-Leu-Tyr-Glu-Ile-Ala-Arg-Arg, acein-1R)
showed dose-dependent inhibitions of ACE, and their IC50 values
were 16 Wmol/l, 500 Wmol/l and 86 Wmol/l, respectively. Acein-1
might be a non-competitive inhibitor, while acein-1R may be an
uncompetitive inhibitor, as shown by Lineweaver-Burk plots.
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1. Introduction
Bioactive substances as starting materials for medicines
have been searched for among almost all natural resources,
including animals, plants, and microorganisms, as well as syn-
thetic compounds [1^7]. One of the best sources of such bio-
active substances is the human body, because substances iso-
lated from the human body can be expected to be non-toxic
and safe for use in medicines. Although numerous substances
have been isolated from the human body, more as yet un-
known bioactive substances are thought to be present in the
human body, especially in proteins. We have been searching
for novel bioactive peptides in proteins in the human body.
Angiotensin-I-converting enzyme (ACE, peptidyl dipeptide
hydrolase, EC 3.4.15.1) has been classically associated with
the renin-angiotensin system which regulates peripheral blood
pressure. ACE raises blood pressure by converting angiotensin
I released from angiotensinogen by renin into the potent vaso-
constrictor angiotensin II. ACE also degrades vasodilative
bradykinin in blood vessels and stimulates the release of al-
dosterone in the adrenal cortex. Consequently, ACE inhibi-
tors may exert an antihypertensive e¡ect [8,9].
Several ACE inhibitory peptides and bradykinin-potentiat-
ing peptides have been isolated from the enzymatic hydroly-
sates of several proteins [10^18]. Weyers et al. isolated several
tryptic peptides from rabbit serum albumin which enhanced
bradykinin activity [12]. Albutensin A, a peptide derived from
the tryptic digest of bovine serum albumin, showed an ACE
inhibitory e¡ect [13]. Other ACE inhibitory peptides were iso-
lated from enzymatic hydrolysates of casein [14^16] and lac-
toglobulin [17,18]. It is also suspected that bioactive peptides
are present in enzymatic hydrolysates of proteins.
In this article, we report a novel ACE inhibitory peptide,
designated acein-1, isolated from the tryptic hydrolysate of
human plasma, and we describe the inhibitory activity of
acein-1, acein-1R and des-7R acein-1. The inhibitory mecha-
nism of acein-1 is non-competitive, while that of acein-1R is
uncompetitive, as shown by Lineweaver-Burk plots.
2. Materials and methods
2.1. Enzymes and other reagents
Freshly frozen plasma for use in transfusion was used as human
plasma. ACE (EC 3.4.15.1, from rabbit lung) and trypsin (EC
3.4.21.4, from bovine pancreas) were purchased from Wako Pure
Chemicals (Osaka, Japan). Hippuryl-histidyl-leucine (HHL) and bra-
dykinin-potentiator B (BPB) were obtained from The Peptide Institute
(Osaka, Japan). Sephadex G-25 and SP-Sephadex C-25 were from
Pharmacia Biotech (Uppsala, Sweden), and the SEP-PAK C18 car-
tridge was from Waters (Milford, MA, USA). All other reagents were
of analytical grade unless otherwise speci¢ed.
2.2. Inhibitory assay for ACE
The inhibitory activity of ACE was measured spectrometrically us-
ing HHL as the substrate, by a modi¢cation of the method of Cush-
man and Cheung [19] as described by Maruyama et al. [15]. Five
millimolar HHL and an appropriate quantity of ACE inhibitor
were dissolved in 100 mM sodium borate bu¡er, pH 8.3, containing
300 mM NaCl, and incubated with 20 mU/ml ACE at 37‡C for 30
min. The concentration of ACE inhibitors needed to inhibit 50% of
ACE activity was de¢ned as the IC50 value. BPB (IC50 = 3.3 WM) was
used as the positive control for ACE inhibition [20].
2.3. Tryptic hydrolysis
Ten milliliters of human plasma was diluted to 1/8 with 50 mM
Tris-HCl bu¡er (pH 8.0). Trypsin was added to the plasma solution at
an enzyme/substrate ratio of 1:50 and hydrolyzed at 37‡C for 3 h. The
reaction was stopped by heating in boiling water for 10 min, and the
hydrolysate was centrifuged at 3000Ug for 20 min to obtain the
supernatant.
2.4. Sephadex G-25 gel ¢ltration
A sample of tryptic hydrolysate was concentrated 5 times by dis-
tillation under reduced pressure, and 10 ml of the concentrate was
applied directly to a Sephadex G-25 column (30U360 mm i.d.) equil-
ibrated with 50 mM Tris-HCl bu¡er (pH 8.0). Elution was used with
the same solution at a £ow rate of 3.6 ml/min. Fractions showing
inhibitory activity were combined.
2.5. SP-Sephadex C-25 cation exchange column chromatography
About 100 ml of the combined fractions from the gel ¢ltration was
applied to an SP-Sephadex C-25 cation exchange column (30U420
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mm i.d.) equilibrated with 10 mM ammonium acetate (pH 4.0). Ma-
terials were eluted with a linear gradient formed with 300 ml of the
same solution in the mixing chamber and 300 ml of the same solution
containing 500 mM ammonium formate in the reservoir, and then 300
ml of the ¢nal solution at a £ow rate of 3.0 ml/min. Eluates from 187
to 228 ml, which showed activity, were combined and desalted by an
SEP-PAK C18 cartridge and evaporated.
2.6. Reversed-phase gradient HPLC
The desalted sample was puri¢ed by reversed-phase high-perform-
ance liquid chromatography (HPLC) with gradient elution. A Gilson
HPLC system was used with an autogradient set (Model 802, 803C,
and 2 of Model 302 pumps, Gilson Medical Electronics, Middleton,
WI, USA). Separation was performed at room temperature on a De-
velosil ODS-5 (Nomura Kagaku, Osaka, Japan) column (4.0U150
mm i.d.) packed in our laboratory. A linear acetonitrile gradient be-
tween 0.1% tri£uoroacetic acid (TFA) in water as solvent A and 80%
acetonitrile with 0.1% TFA in water as solvent B was used as follows:
0% B for 20 min, 0^40% B for 60 min, 40% B for 30 min, and 100% B
for 10 min. The £ow rate was 1.0 ml/min, and the e¥uent was moni-
tored continuously at 215 nm. All peaks were fractionated and evapo-
rated for measuring inhibitory activity.
2.7. Reversed-phase isocratic HPLC
The active fraction was further puri¢ed by reversed-phase isocratic
HPLC. The HPLC system used was the same as the gradient HPLC
system. Separation was performed on a tandem-linked Develosil
ODS-5 column (4.0U150 mm i.d.) at room temperature. Twenty per-
cent of acetonitrile with 0.1% TFA was used as the e¥uent for the
isolation of the peptide. The £ow rate was 0.5 ml/min, and the e¥uent
was monitored continuously at 215 nm. An active fraction was col-
lected and evaporated.
2.8. Amino acid sequence analysis and mass spectrometry
The amino acid sequence was determined using Edman degradation
on a pulsed-liquid protein sequencer, equipped with an on-line phe-
nylthiohydantoin amino acid analyzer (Applied Biosystems 477A/
120A, Foster City, CA, USA). The mass analysis of the peptides
was carried out using a matrix-assisted laser desorption/ionization
time-of-£ight (MALDI-TOF) mass spectrometer (Kompact MALDI
IV, Shimadzu, Kyoto, Japan).
2.9. Peptide synthesis
Some of the peptides were synthesized using Fmoc solid-phase syn-
thesis at Biologica, Nagoya, Japan, and some were kindly provided by
Dr. Toshifumi Akizawa, Setsunan University, Osaka, Japan.
3. Results and discussion
With the use of HHL as the substrate, the tryptic hydro-
lysate of human plasma was found to have signi¢cant ACE
inhibitory activity. The tryptic hydrolysate for 3 h reached the
maximum inhibition when various time periods of hydrolysis
were carried out and the activity remained unchanged for at
least 24 h, while a plasma sample without tryptic digestion
had no activity. An active fraction from a Sephadex G-25
column was eluted at almost the same position as peptides
of molecular weight of about 1000 (data not shown). Frac-
tions eluted from SP-Sephadex C-25 cation exchange chroma-
tography which showed activity were collected and concen-
trated through a SEP-PAK C18 cartridge. The sample was
puri¢ed by reversed-phase HPLC with gradient elution. The
peptic sample eluted at around 20% acetonitrile showed sig-
ni¢cant inhibitory activity, and a single peak isolation was
performed by isocratic HPLC with an eluent of 0.1% TFA
containing 20% acetonitrile.
In the amino acid sequencing analysis, the puri¢ed peptide
was found to be a heptapeptide, the sequence of which was
Tyr-Leu-Tyr-Glu-Ile-Ala-Arg. The mass number obtained
from this peptide was consistent with the sequence obtained
by the mass spectrometric determination (data not shown). In
addition, the puri¢ed peptide was identical to the synthetic
heptapeptide on isocratic HPLC analysis. Consequently, the
puri¢ed peptide was identi¢ed as the heptapeptide, Tyr-Leu-
Tyr-Glu-Ile-Ala-Arg, and designated acein-1.
The amino acid sequence of acein-1 was found to be iden-
tical to that of f(138^144) in human serum albumin by pro-
tein-database analysis. Acein-1 was found to originate from
human serum albumin by tryptic digestion because f(137), the
former amino acid of acein-1 in it, was Lys and C-terminus of
acein-1 was Arg. Bovine, felca and porcine serum albumins
have the same amino acid sequence as acein-1. On the other
hand rabbit, sheep and horse serum albumins involve Tyr-
Leu-Tyr-Glu-Val-Ala-Arg, 5Ile residue in acein-1 was replaced
by Val. Synthetic rabbit acein-1 showed the similar ACE in-
hibitory e¡ect to acein-1 (data not shown).
Several peptides related to ACE inhibition have been iso-
lated from tryptic hydrolysates of serum albumins. One is
albutensin A, derived from the tryptic hydrolysate of bovine
serum albumin as a contractile peptide for guinea pig ileum;
its amino acid sequence was reported as Ala-Leu-Lys-Ala-
Trp-Ser-Val-Ala-Arg by Chiba and Yoshikawa [13]. The ami-
no acid sequence of human albutensin A, Ala-Phe-Lys-Ala-
Trp-Ala-Val-Ala-Arg, corresponds to f(210^218) of human
serum albumin. Only human albutensin A has been reported
previously to have ACE inhibitory activity among the enzy-
matic hydrolysates of human proteins. Other such peptides
are two bradykinin-potentiating peptides, peptide-AVI (Leu-
Val-Glu-Ser-Ser-Lys) and peptide-AVII (Thr-Pro-Val-Ser-
Glu-Lys), both of which were isolated from rabbit serum al-
bumin by Weyers et al. [12]. The corresponding sequences of
human serum albumin were estimated to be Leu-Val-Ala-Ala-
Ser-Gln, f(475^480) for peptide-AVI and Thr-Pro-Val-Ser-
Asp-Arg, f(467^472) for peptide-AVII. These corresponding
peptides might have inhibitory activity against ACE; this
has not yet been examined. Acein-1 is a novel ACE inhibitory
peptide derived from the tryptic hydrolysate of human serum
albumin.
Acein-1R, the C-terminal extended octapeptide of acein-1
with the amino acid sequence Tyr-Leu-Tyr-Glu-Ile-Ala-Arg-
Arg, was estimated to have inhibitory activity because many
ACE inhibitors have a C-terminal Arg, as does acein-1 [14,18].
Acein-1 and acein-1R were examined for ACE inhibitory ac-
tivity and compared with that of des-7R acein-1 (Tyr-Leu-
Tyr-Glu-Ile-Ala), which has no C-terminal Arg. The dose-de-
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Fig. 1. Dose-dependent inhibition of ACE by acein-1 (b), acein-1R
(R) and des-7R acein-1 (F). Each point represents the mean value
of three experiments.
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pendent relationship of these three synthetic peptides regard-
ing ACE inhibition is shown in Fig. 1. The positive charge of
the C-terminal Arg was indicated to contribute substantially
to the ACE inhibitory activity, and an Arg residue was found
to be more e¡ective than Arg-Arg on the C-terminus. Acein-1,
which originates from the tryptic hydrolysate of human serum
albumin, was the most active among the three peptides. The
IC50 values of acein-1, acein-1R and des-7R acein-1 were 16
Wmol/l, 86 Wmol/l and 500 Wmol/l, respectively.
Acein-1 and acein-1R show the signi¢cant IC50 values
which were similar to those of other ACE inhibitory peptides
derived from tryptic hydrolysates of several proteins; the IC50
of bovine albutensin A (from bovine serum albumin) was
reported as 3.4 Wmol/l [13], while that of human albutensin
A was not reported; Ala-Leu-Pro-Met-His-Ile-Arg (from bo-
vine L-lactoglobulin) as 42.6 Wmol/l [17] ; CEI12, Phe-Phe-Val-
Ala-Pro-Phe-Pro-Glu-Val-Phe-Gly-Lys (from bovine casein)
as 77 Wmol/l [15]; and CEIb7, Ala-Val-Pro-Tyr-Pro-Gln-Arg
(from bovine casein) as 15 Wmol/l [16].
To clarify the inhibition mechanism kinetically, two sets of
rate experiments for each peptide were carried out, and the
results are plotted double reciprocally in Fig. 2. The Linewea-
ver-Burk plots of acein-1 (Fig. 2A) showed that it is a non-
competitive inhibitor, with an intercept on the 1/[S] axis [21].
These plots suggested that acein-1 could not bind to the cata-
lytic site of ACE and that it could not be hydrolyzed by ACE.
In contrast, acein-1R showed uncompetitive inhibition, gener-
ating almost parallel lines in Fig. 2B. The reason for the
di¡erence between the inhibitory mechanisms that acein-1 is
a non-competitive inhibitor and that acein-1R, which only
contains an additional C-terminal Arg to acein-1, is an un-
competitive one is yet to be elucidated. However, it was esti-
mated that acein-1R could be a substrate of ACE as well as
being an ACE inhibitor, because des-7R acein-1, the ACE
hydrolysate of acein-1R, had ACE inhibitory activity. The
Lineweaver-Burk plots of acein-1R may therefore indicate
the cooperative inhibition of acein-1R with des-7R acein-1.
Further experiments are needed to examine the presumption.
It should be noted that peptides derived from food proteins
such as casein hydrolysates have been shown to have signi¢-
cant physiological e¡ects and have been used in an attempt to
prevent hypertension [10]. The present results suggest that
acein-1 could be used as a starting material for anti-hyper-
tensive drugs against ACE, although it is as yet unknown
whether acein-1 is released from serum albumin by endoge-
nous tryptic hydrolysis in the human body to inhibit ACE as
part of the physiological regulation.
Consequently, acein-1 could represent an example of the
human body as a potential resource for starting materials
for medicines such as ACE inhibitors.
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Fig. 2. Lineweaver-Burk plots of the inhibition of ACE by acein-1
(A) and acein-1R (B). Each point represents the mean value of three
experiments. ACE activities were measured in the absence (b) or in
the presence (E) of 25 Wmol/l acein-1 (A) or 50 Wmol/l acein-1R (B).
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